Apoferritin-mediated doxorubicin internalization through transferrin receptor 1
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F17%3A43912629" target="_blank" >RIV/62156489:43210/17:43912629 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216305:26620/17:PU128371
Výsledek na webu
<a href="https://mnet.mendelu.cz/mendelnet2017/mnet_2017_full.pdf" target="_blank" >https://mnet.mendelu.cz/mendelnet2017/mnet_2017_full.pdf</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Apoferritin-mediated doxorubicin internalization through transferrin receptor 1
Popis výsledku v původním jazyce
This work is aimed at the possibilities of targeted drug delivery into the tumour tissue. This approach can greatly reduce the otherwise serious side effects of conventional treatment - systemic toxicity. For this purpose, ubiquitous protein cage apoferritin was employed as a carrier of cytotoxic drugs. Its molecule size of 10-12 nm allows it to employ the effect of increased permeability and retention as well as to avoid renal clearance. The cellular uptake of this carrier is known to be mediated via the transferrin receptor 1 (TfR1), which is overexpressed on metabolically highly active cells, such as cancer cells. Therefore, apoferritin's ability to deliver drug molecules to site-of-action was tested using cell lines with high, medium and low expression of TfR1. The optimal conditions for studying the expression of TfR1 using western blotting were as follows: lysate of 50,000 cells applied in non-reducing non-denaturing buffer and the concentration of the primary antibody of 1.0 µg/mL. The properties of encapsulated doxorubicin were not affected by apoferritin, thus preserving its toxicity for cells with high level of TfR1expression (30% growth inhibition of these cells after 24 h of treatment). The suitable usage of apoferritin as a nanocarrier for chemotherapeutic delivery was confirmed in this work.
Název v anglickém jazyce
Apoferritin-mediated doxorubicin internalization through transferrin receptor 1
Popis výsledku anglicky
This work is aimed at the possibilities of targeted drug delivery into the tumour tissue. This approach can greatly reduce the otherwise serious side effects of conventional treatment - systemic toxicity. For this purpose, ubiquitous protein cage apoferritin was employed as a carrier of cytotoxic drugs. Its molecule size of 10-12 nm allows it to employ the effect of increased permeability and retention as well as to avoid renal clearance. The cellular uptake of this carrier is known to be mediated via the transferrin receptor 1 (TfR1), which is overexpressed on metabolically highly active cells, such as cancer cells. Therefore, apoferritin's ability to deliver drug molecules to site-of-action was tested using cell lines with high, medium and low expression of TfR1. The optimal conditions for studying the expression of TfR1 using western blotting were as follows: lysate of 50,000 cells applied in non-reducing non-denaturing buffer and the concentration of the primary antibody of 1.0 µg/mL. The properties of encapsulated doxorubicin were not affected by apoferritin, thus preserving its toxicity for cells with high level of TfR1expression (30% growth inhibition of these cells after 24 h of treatment). The suitable usage of apoferritin as a nanocarrier for chemotherapeutic delivery was confirmed in this work.
Klasifikace
Druh
D - Stať ve sborníku
CEP obor
—
OECD FORD obor
10608 - Biochemistry and molecular biology
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název statě ve sborníku
MendelNet 2017: Proceedings of International PhD Students Conference
ISBN
978-80-7509-529-9
ISSN
—
e-ISSN
neuvedeno
Počet stran výsledku
6
Strana od-do
894-899
Název nakladatele
Mendelova univerzita v Brně
Místo vydání
Brno
Místo konání akce
Brno
Datum konání akce
8. 11. 2017
Typ akce podle státní příslušnosti
WRD - Celosvětová akce
Kód UT WoS článku
000440194500160